Zobrazeno 1 - 10
of 119
pro vyhledávání: '"S Weinreich"'
Autor:
Ben Vandermeer, Ingeborg van der Tweel, Marijke C. Jansen-van der Weide, Stephanie S. Weinreich, Despina G. Contopoulos-Ioannidis, Dirk Bassler, Ricardo M. Fernandes, Lisa Askie, Haroon Saloojee, Paola Baiardi, Susan S. Ellenberg, Johanna H. van der Lee
Publikováno v:
BMC Medical Research Methodology, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background We wished to compare the nuisance parameters of pediatric vs. adult randomized-trials (RCTs) and determine if the latter can be used in sample size computations of the former. Methods In this meta-epidemiologic empirical evaluatio
Externí odkaz:
https://doaj.org/article/515fa94132934a3a96fd212a7eb3a4ab
Autor:
Stephanie S. Weinreich, Charlotte Vrinten, Marja R. Kuijpers, Alexander F. Lipka, Kirsten J. M. Schimmel, Erik W. van Zwet, Christine Gispen-de Wied, Yechiel A. Hekster, Jan J. G. M. Verschuuren, Martina C. Cornel
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 12, Iss 1, Pp 1-18 (2017)
Abstract Background Inexpensive medicines with a long history of use may currently be prescribed off-label for rare indications. Reimbursement is at the discretion of health insurance companies, and may be unpredictable. The example addressed was eph
Externí odkaz:
https://doaj.org/article/89b8aba7bbad472cb91c27a0db2bdc16
Autor:
Charlotte M. W. Gaasterland, Marijke C. Jansen-van der Weide, Stephanie S. Weinreich, Johanna H. van der Lee
Publikováno v:
BMC Medical Research Methodology, Vol 16, Iss 1, Pp 1-22 (2016)
Abstract Background One of the main challenges for drug evaluation in rare diseases is the often heterogeneous course of these diseases. Traditional outcome measures may not be applicable for all patients, when they are in different stages of their d
Externí odkaz:
https://doaj.org/article/df62642dceab4c1fb4d3e58615504232
Publikováno v:
Proceedings of the Design Society: DESIGN Conference. 1:1395-1404
Innovation portfolio management (IPM) aims at selecting ideas with regard to their potential for innovation and measuring them considering customer and business value. The evaluation of benefits and risk is especially challenging for disruptive innov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d6eb0142085b0fd5a7059e89ee6ed68
https://doi.org/10.1017/dsd.2020.155
https://doi.org/10.1017/dsd.2020.155
Publikováno v:
European Journal of Human Genetics
Rigter, T, Klein, D, Weinreich, S S & Cornel, M C 2021, ' Moving somatic gene editing to the clinic : routes to market access and reimbursement in Europe ', European Journal of Human Genetics, vol. 29, no. 10, pp. 1477-1484 . https://doi.org/10.1038/s41431-021-00877-y
European Journal of Human Genetics, 29(10), 1477-1484. Nature Publishing Group
Rigter, T, Klein, D, Weinreich, S S & Cornel, M C 2021, ' Moving somatic gene editing to the clinic : routes to market access and reimbursement in Europe ', European Journal of Human Genetics, vol. 29, no. 10, pp. 1477-1484 . https://doi.org/10.1038/s41431-021-00877-y
European Journal of Human Genetics, 29(10), 1477-1484. Nature Publishing Group
Somatic gene editing (SGE) holds great promise for making genetic therapy possible for many monogenic conditions very soon. Is our current system of European market authorization and reimbursement ready for the expected tsunami of gene therapies? At
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6633a0e426b38fa3fc95e2015b5a5f28
https://pubmed.ncbi.nlm.nih.gov/33850300
https://pubmed.ncbi.nlm.nih.gov/33850300
Autor:
Carla G. van El, M. Radstake, Lidewij Henneman, Martina C. Cornel, Sarah R. van Teeffelen, Stephanie S Weinreich, Conor M.W. Douglas
Publikováno v:
van Teeffelen, S R, Douglas, C M W, van El, C G, Weinreich, S S, Henneman, L, Radstake, M & Cornel, M C 2016, ' Mothers' Views on Longer Storage of Neonatal Dried Blood Spots for Specific Secondary Uses ', Public Health Genomics, vol. 19, no. 1, pp. 25-33 . https://doi.org/10.1159/000441516
Public Health Genomics, 19(1), 25-33. Karger
Public Health Genomics, 19(1), 25-33. S. Karger AG
Public Health Genomics, 19(1), 25-33. Karger
Public Health Genomics, 19(1), 25-33. S. Karger AG
Background: Neonatal dried blood spots (DBS) present a wealth of data. Currently, many countries discuss DBS storage, management and use. We collected data in the Netherlands on the awareness and views of an unheard stakeholder: mothers (-to-be). Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::203fbb08f133f41e3da0822619de8721
https://doi.org/10.1159/000441516
https://doi.org/10.1159/000441516
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Erik W. van Zwet, Kirsten J. M. Schimmel, Yechiel A. Hekster, Martina C. Cornel, Jan J.G.M. Verschuuren, Christine C. Gispen-de Wied, Stephanie S Weinreich, Charlotte Vrinten, Alexander F. Lipka, Marja R. Kuijpers
Publikováno v:
Weinreich, S S, Vrinten, C, Kuijpers, M R, Lipka, A F, Schimmel, K J M, Van Zwet, E W, Gispen-De Wied, C, Hekster, Y A, Verschuuren, J J G M & Cornel, M C 2017, ' Aggregated N-of-1 trials for unlicensed medicines for small populations : an assessment of a trial with ephedrine for myasthenia gravis ', Orphanet Journal of Rare Diseases, vol. 12, no. 1, 88 . https://doi.org/10.1186/s13023-017-0636-y
Orphanet Journal of Rare Diseases, Vol 12, Iss 1, Pp 1-18 (2017)
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases, 12(1):88. BioMed Central
Orphanet Journal of Rare Diseases, 12
Orphanet Journal of Rare Diseases, Vol 12, Iss 1, Pp 1-18 (2017)
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases, 12(1):88. BioMed Central
Orphanet Journal of Rare Diseases, 12
Background Inexpensive medicines with a long history of use may currently be prescribed off-label for rare indications. Reimbursement is at the discretion of health insurance companies, and may be unpredictable. The example addressed was ephedrine as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff4bd4bfed65f26a37c7c77f6ab1aac
https://doi.org/10.1186/s13023-017-0636-y
https://doi.org/10.1186/s13023-017-0636-y
Autor:
Erik W. van Zwet, Kirsten J. M. Schimmel, Jan J.G.M. Verschuuren, Martina C. Cornel, Yechiel A. Hekster, Stephanie S Weinreich, Marja R. Kuijpers, Alexander F. Lipka, Charlotte Vrinten
Publikováno v:
Neuromuscular Disorders, 27(3), 259-265. Elsevier Limited
Lipka, A F, Vrinten, C, van Zwet, E W, Schimmel, K J M, Cornel, M C, Kuijpers, M R, Hekster, Y A, Weinreich, S S & Verschuuren, J J G M 2017, ' Ephedrine treatment for autoimmune myasthenia gravis ', Neuromuscular Disorders, vol. 27, no. 3, pp. 259-265 . https://doi.org/10.1016/j.nmd.2016.11.009
Neuromuscular Disorders, 27(3), 259-265
Lipka, A F, Vrinten, C, van Zwet, E W, Schimmel, K J M, Cornel, M C, Kuijpers, M R, Hekster, Y A, Weinreich, S S & Verschuuren, J J G M 2017, ' Ephedrine treatment for autoimmune myasthenia gravis ', Neuromuscular Disorders, vol. 27, no. 3, pp. 259-265 . https://doi.org/10.1016/j.nmd.2016.11.009
Neuromuscular Disorders, 27(3), 259-265
We studied the effect and safety of ephedrine as add-on treatment for patients with myasthenia gravis with acetylcholine receptor antibodies (AChR MG), who do not sufficiently respond to standard treatment. Four patients with AChR MG were included in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad945b2ea9605ec22ae06db64161452e
https://hdl.handle.net/1887/114492
https://hdl.handle.net/1887/114492
Autor:
Marlies Wijsenbeek-Lourens, Rémy L M Mostard, Stephanie S. Weinreich, Carmen D. Dirksen, Adriënne H Rotteveel, Xana van Jaarsveld, Merel Kimman
Publikováno v:
1.5 Diffuse Parenchymal Lung Disease.
Background: Optimal treatment of IPF remains challenging. Recent guidelines recommend two anti-fibrotic agents: pirfenidone and nintedanib. Besides traditional physiological end-points such as forced vital capacity, the patient9s perceived effectiven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de27c031a61773e099a9cfc8b0e69acd
https://doi.org/10.1183/13993003.congress-2016.pa793
https://doi.org/10.1183/13993003.congress-2016.pa793